Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Aphria Inc. APHA

Aphria, which is headquartered in Ontario, produces and sells medicinal and recreational cannabis. The company operates through retail and wholesale channels in Canada and internationally. Aphria is a main distributor of medical cannabis to Germany and has operations in over 10 countries outside of Canada. However, it does not have exposure to the U.S. CBD or THC markets due to the constraints of federal prohibition. It has some U.S. exposure through the acquisition of SweetWater, a craft brewer


NDAQ:APHA - Post by User

Bullboard Posts
Comment by Viking49on Aug 09, 2018 4:44pm
162 Views
Post# 28436210

RE:RE:Enough Said!!! Bring on Budweiser!!!

RE:RE:Enough Said!!! Bring on Budweiser!!!
jayjay2020 wrote:
JTDOUBLE wrote:
Aph should be a good choice for Bud considering they are building 50 millions state of Art extractor!!!

Bud got no choice Corona and Molsons Coors are in!!

Logisticals coup if happens and chances of Aph is good!!!

Bud comes in ...Easy double here!!! 

 
Not under the same terms that Molson did with HEXO.  No way!  That deal was bad!  Molson is in the marijuana market with no cash infusion.  At least Constellation bought into WEED. 



No need for a beverage company affiliation unless it is a really good deal for Aphria.

Build the extraction facility and develop water soluble concentrates with the desired psychoactive effects...........and the bulk of the beverage industry will be knocking on the door!  Aphria will dominate the concentrate segment with their production and pricing capability!  This time next year I predict the majority of Aphria’s cannabis production will be converted to concentrates for the wave of new cannabis products that will be allowed late 2019. I anticipate a shortage of cannabis concentrate in the early going.  There could still be a shortage for bud until late 2019 but upgrading to concentrate upgrades the margin.

Big picture......I would rather have affiliation or buyout from a large pharmaceutical company.  And Aphria’s world strategy makes that scenario more likely!


Bullboard Posts